Ignite Creation Date:
2024-05-06 @ 1:06 AM
Last Modification Date:
2024-10-26 @ 10:59 AM
Study NCT ID:
NCT01730092
Status:
RECRUITING
Last Update Posted:
2024-07-15
First Post:
2012-11-17
Brief Title:
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
Sponsor:
National Institutes of Health Clinical Center CC
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
A Natural History Study of Novel Biomarkers in Pulmonary Arterial Hypertension
Status:
RECRUITING
Status Verified Date:
2024-07-29
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Background
- High blood pressure in the lungs known as pulmonary arterial hypertension PAH is a rare disorder Some people have disease-associated PAH and some have PAH from an unknown cause Researchers want to follow the natural history of all PAH patients to understand how PAH progresses in order to discover targets for future research into new treatments To further identify treatment targets they will compare healthy volunteers to patients with PAH
Objectives
- To study the natural history of PAH
Eligibility
Individuals at least 18 years of age who have PAH
Healthy volunteers at least 18 years of age
Design
Participants with PAH will have periodic visits to the National Institutes of Health Clinical Center After the first visit they will return in 6 months and then yearly or every other year for as long as the study continues
The first visit will take up to 3 days It will involve the following tests
Physical exam and medical history
Blood and urine samples
Heart and lung function tests and imaging studies
Six-minute walk test
Questions about exercise and physical activity
Healthy volunteers will have only one visit to the Clinical Center during which they will undergo screening tests and complete many of the same tests as patients with PAH
- High blood pressure in the lungs known as pulmonary arterial hypertension PAH is a rare disorder Some people have disease-associated PAH and some have PAH from an unknown cause Researchers want to follow the natural history of all PAH patients to understand how PAH progresses in order to discover targets for future research into new treatments To further identify treatment targets they will compare healthy volunteers to patients with PAH
Objectives
- To study the natural history of PAH
Eligibility
Individuals at least 18 years of age who have PAH
Healthy volunteers at least 18 years of age
Design
Participants with PAH will have periodic visits to the National Institutes of Health Clinical Center After the first visit they will return in 6 months and then yearly or every other year for as long as the study continues
The first visit will take up to 3 days It will involve the following tests
Physical exam and medical history
Blood and urine samples
Heart and lung function tests and imaging studies
Six-minute walk test
Questions about exercise and physical activity
Healthy volunteers will have only one visit to the Clinical Center during which they will undergo screening tests and complete many of the same tests as patients with PAH
Detailed Description:
Introduction
Pulmonary arterial hypertension PAH is a rare disorder associated with poor survival Endothelial dysfunction resulting from 1 genetic susceptibility and 2 a triggering stimulus that initiates pulmonary vascular injury the two-hit hypothesis appears to play a central role both in the pathogenesis and progression of PAH Inflammation appears to drive this dysfunctional endothelial phenotype propagating cycles of injury and repair in genetically susceptible patients with idiopathic PAH IPAH and patients with disease-associated PAH However despite mounting evidence of vascular inflammation in patients with PAH detailed phenotypic studies are lacking on the temporal evolution of this process and its contribution to right ventricular RV and pulmonary vascular remodeling We hypothesize that a detailed characterization of the temporal evolution of vascular inflammation in PAH and its impact on RV and pulmonary vascular function will add prognostic value to traditional measures of disease severity and suggest novel therapeutic targets for future research
Objectives
Patients with IPAH and disease-associated PAH will be recruited to the NIH and enrolled in this natural history study investigating the ability of circulating markers of vascular inflammation as well as high-resolution cardiac magnetic resonance imaging MRI to accurately stage severity of disease andor predict clinically relevant outcomes
Methods
The total population for the study will be 150 PAH subjects and approximately 55 age and gender matched controls ie each healthy volunteer is matched to less than or equal to 3 PAH subjects
PAH subjects will undergo 1 standard clinical examinations including 6-minute walk distance and echocardiography 2 cardiopulmonary exercise testing 3 markers of coagulation and fibrotic disease 4 plasma profiling of inflammatory
markers 5 gene expression profiling of peripheral blood mononuclear cells PBMCs 6 high-resolution MRI-based determination of pulmonary vascularand RV structure and function and 7 Cardiac CT scan
Plasma markers of endothelial inflammation PBMC expression profiles and high-resolution cardiac MRI will also be studied in age and gender matched controls to define normal ranges and variability for each of these novel assessments Comparison of these results to PAH subjects at baseline will be used to determine the degree to which these investigative tests distinguish PAH patients from healthy subjects Likewise baseline clinical evaluations of PAH subjects will be used to examine whether any novel test inflammatory markers or cardiac MRI accurately classifies patients according to their disease severity In addition these tests will be investigated prospectively for their ability to predict PAH disease progression Disease progression will be defined prospectively as a decrease in the 6-minute walk distance of greater than or equal to10 from baseline or clinical worsening requiring an escalation in therapy hospitalization due to right heart failure transplantation or death
Additional plasma will be collected from PAH subjects and agegender matched control subjects This material will be used to probe for new biomarkers and inflammatory factors using discovery based approaches ie Proteomics and pulmonary artery endothelial cell bioassay
Pulmonary arterial hypertension PAH is a rare disorder associated with poor survival Endothelial dysfunction resulting from 1 genetic susceptibility and 2 a triggering stimulus that initiates pulmonary vascular injury the two-hit hypothesis appears to play a central role both in the pathogenesis and progression of PAH Inflammation appears to drive this dysfunctional endothelial phenotype propagating cycles of injury and repair in genetically susceptible patients with idiopathic PAH IPAH and patients with disease-associated PAH However despite mounting evidence of vascular inflammation in patients with PAH detailed phenotypic studies are lacking on the temporal evolution of this process and its contribution to right ventricular RV and pulmonary vascular remodeling We hypothesize that a detailed characterization of the temporal evolution of vascular inflammation in PAH and its impact on RV and pulmonary vascular function will add prognostic value to traditional measures of disease severity and suggest novel therapeutic targets for future research
Objectives
Patients with IPAH and disease-associated PAH will be recruited to the NIH and enrolled in this natural history study investigating the ability of circulating markers of vascular inflammation as well as high-resolution cardiac magnetic resonance imaging MRI to accurately stage severity of disease andor predict clinically relevant outcomes
Methods
The total population for the study will be 150 PAH subjects and approximately 55 age and gender matched controls ie each healthy volunteer is matched to less than or equal to 3 PAH subjects
PAH subjects will undergo 1 standard clinical examinations including 6-minute walk distance and echocardiography 2 cardiopulmonary exercise testing 3 markers of coagulation and fibrotic disease 4 plasma profiling of inflammatory
markers 5 gene expression profiling of peripheral blood mononuclear cells PBMCs 6 high-resolution MRI-based determination of pulmonary vascularand RV structure and function and 7 Cardiac CT scan
Plasma markers of endothelial inflammation PBMC expression profiles and high-resolution cardiac MRI will also be studied in age and gender matched controls to define normal ranges and variability for each of these novel assessments Comparison of these results to PAH subjects at baseline will be used to determine the degree to which these investigative tests distinguish PAH patients from healthy subjects Likewise baseline clinical evaluations of PAH subjects will be used to examine whether any novel test inflammatory markers or cardiac MRI accurately classifies patients according to their disease severity In addition these tests will be investigated prospectively for their ability to predict PAH disease progression Disease progression will be defined prospectively as a decrease in the 6-minute walk distance of greater than or equal to10 from baseline or clinical worsening requiring an escalation in therapy hospitalization due to right heart failure transplantation or death
Additional plasma will be collected from PAH subjects and agegender matched control subjects This material will be used to probe for new biomarkers and inflammatory factors using discovery based approaches ie Proteomics and pulmonary artery endothelial cell bioassay
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 13-CC-0012 | None | None | None |